Healthcare Services

Next Generation Cancer Diagnostics Market Outlook Assessing Future Opportunities And Growth Prospects

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Next Generation Cancer Diagnostics Market Projected To Expand During 2026–2030?

The next generation cancer diagnostics market size has experienced swift expansion in recent years. This market is projected to grow from $14.4 billion in 2025 to $16.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. Historically, this growth can be attributed to factors such as increasing cancer incidence rates, advancements in genomic sequencing technologies, a rise in the clinical adoption of biomarker-based diagnostics, an expansion of oncology research funding, and a growing demand for precision diagnostics.

The next generation cancer diagnostics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a valuation of $26.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.9%. This expansion during the projected timeframe is largely due to the wider embrace of personalized medicine strategies, heightened capital expenditure in advanced cancer screening initiatives, an escalating reliance on minimally invasive diagnostic techniques, the broader development of companion diagnostics, and the greater incorporation of AI-powered clinical decision support systems. Key developments anticipated for this period encompass the increased uptake of liquid biopsy technologies, a surging application of multi-omics diagnostic platforms, the deepening integration of AI-based cancer analytics, the spread of personalized oncology diagnostics, and a heightened emphasis on identifying cancer at earlier stages.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp

Which Significant Factors Are Encouraging Growth In The Next Generation Cancer Diagnostics Market?

The escalating need for personalized medicines is anticipated to propel the expansion of the next generation cancer diagnostics market moving forward. Personalized medicines are medical treatments specifically tailored to an individual’s genetic makeup, lifestyle, and environment, ensuring the most effective therapy for that particular patient. This heightened demand for personalized medicines arises from the increasing prevalence of chronic and rare diseases, which necessitate targeted, patient-specific therapies to achieve more favorable treatment outcomes. Next generation cancer diagnostics enable personalized medicine by offering precise molecular insights that guide customized treatment strategies based on an individual patient’s unique genetic and tumor profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, marking a substantial increase from the six approvals recorded in 2022. Consequently, the growing demand for personalized medicines is driving the growth of the next generation cancer diagnostics market.

How Are Different Segment Groups Identified Within The Next Generation Cancer Diagnostics Market?

The next generation cancer diagnostics market covered in this report is segmented –

1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer

3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis

4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis

5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings

Subsegments:

1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing

2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems

3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays

4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays

5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays

6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems

What Trends Are Driving Changes In The Next Generation Cancer Diagnostics Market?

Leading companies within the neurotrophic keratitis market are concentrating on creating sophisticated gene-therapy options, including redosable eye-drop treatments. These innovations aim to enhance corneal healing, ensure consistent nerve growth factor (NGF) expression, and alleviate the burden of treatment for patients. Redosable eye-drop gene therapy involves a medical strategy where genes that encode NGF are directly delivered to the cornea, allowing for extended NGF production and supporting nerve regeneration over time. A notable example is Krystal Biotech, a US-based biotechnology company, which announced in July 2025 that the initial patient had received a dose in its Phase 1/2 EMERALD 1 study. This trial is a randomized, double-masked, placebo-controlled study enrolling up to 27 adults suffering from stage 2 or 3 neurotrophic keratitis. KB801, intended for twice-weekly administration over eight weeks, is designed to safely encourage corneal healing while substantially lessening the treatment frequency compared to current six-times-a-day recombinant NGF eye drops.

Who Are The Key Market Participants In The Next Generation Cancer Diagnostics Market?

Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.

Access The Complete Next Generation Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/global-next-generation-cancer-diagnostics-market-report

Which Region Leads The Next Generation Cancer Diagnostics Market By Size?

North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Next Generation Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=30336&type=smp

Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company

Peripheral Neuropathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Chronic Pain Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Neuralgia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795